Privia Health Group Inc’s filing revealed that its Officer Mountcastle David acquired Company’s shares for reported $2.51 million on Feb 14 ’25. In the deal valued at $25.15 per share,100,000 shares were bought.
Then, Mehrotra Parth sold 135,142 shares, generating $2,500,127 in total proceeds. Upon selling the shares at $18.50, the Chief Executive Officer now owns 247,771 shares.
Before that, Mehrotra Parth bought 135,142 shares. Privia Health Group Inc shares valued at $2,500,719 were divested by the Officer at a price of $18.50 per share.
Needham initiated its Privia Health Group Inc [PRVA] rating to a Buy in a research note published on January 10, 2025; the price target was $25. A number of analysts have revised their coverage, including Macquarie’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. KeyBanc Capital Markets began covering PRVA with “an Overweight” recommendation on October 11, 2024. Robert W. Baird started covering the stock on May 30, 2024. It rated PRVA as “an Outperform”.
Price Performance Review of PRVA
On Tuesday, Privia Health Group Inc [NASDAQ:PRVA] saw its stock fall -0.79% to $25.04. Over the last five days, the stock has gained 5.08%. Privia Health Group Inc shares have risen nearly 28.08% since the year began. Nevertheless, the stocks have risen 17.72% over the past one year. While a 52-week high of $25.49 was reached on 02/18/25, a 52-week low of $15.92 was recorded on 01/02/25. SMA at 50 days reached $21.75, while 200 days put it at $19.48.
Levels Of Support And Resistance For PRVA Stock
The 24-hour chart illustrates a support level at 24.80, which if violated will result in even more drops to 24.55. On the upside, there is a resistance level at 25.46. A further resistance level may holdings at 25.88. The Relative Strength Index (RSI) on the 14-day chart is 72.53, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.51, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.53%. Stochastics %K at 89.05% indicates the stock is a selling.
The most recent change occurred on April 22, 2024 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
